Form 4: Seres Therapeutics Executive Sells Shares to Cover Taxes After RSU Vesting
SEC Form 4 Filing
Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, sold 891 shares of common stock on May 15, 2024, to cover taxes related to the vesting of restricted stock units.
Summary
- On May 15, 2024, Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, sold 891 shares of the company's common stock.
- The sale was executed at a weighted average price of $0.94 per share, with individual transactions ranging from $0.9206 to $0.94.
- This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on April 13, 2023.
- The purpose of the sale was to cover tax obligations associated with the vesting of restricted stock units (RSUs).
- Henn also acquired 2,812 shares through the vesting of RSUs on the same day.
- Following these transactions, Henn directly owns 65,357 shares of Seres Therapeutics common stock and 30,938 restricted stock units.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction (stock sale for tax purposes) and doesn't indicate any significant positive or negative sentiment.
Positives
- The use of a pre-arranged Rule 10b5-1 trading plan suggests the sale was planned and not based on immediate market conditions or insider information.
Industry Context
Insider transactions are routinely monitored and reported to the SEC. Sales to cover taxes on vested equity are common.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units that vest over time.
- Rule 10b5-1 plans are a standard tool for insiders to manage stock sales while avoiding accusations of trading on non-public information.
- The size of the transaction is relatively small, suggesting it is a routine tax-related sale.
Stakeholder Impact
- The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but the impact is likely to be minimal given the context of tax obligations and the use of a 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| April 13, 2023 | Date of adoption of Rule 10b5-1 trading plan |
| February 15, 2024 | 25% of the restricted stock units vested and settled |
| May 15, 2024 | Date of stock sale and RSU vesting |
| May 17, 2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.